MCP to Produce Clinical and Commercial Supply of an Innovative Injectable

MCP Pharmaceuticals to Produce Clinical and Commercial Supply of an Innovative Injectable

PARSIPPANY, NJ June 05, 2012 — MCP Pharmaceuticals, a provider of global contract manufacturing services for sterile products has entered into an agreement with an undisclosed pharmaceutical company to produce clinical and commercial supply of an innovative injectable used in the cardiovascular setting. Stuart Hinchen president and CEO of MCP stated, “We are pleased to serve this important customer and recognize that being selected to produce this injectable is based on our expertise with complex formulations coupled with our competence in both clinical supply and commercial supply.”

Hinchen noted, “MCP’s extensive experience working with products through their life cycle starting with clinical trials through approval, product launch and global commercialization provides customers with a measure of confidence allowing them to focus on their day-to-day business priorities.” MCP’s Rochester, Michigan manufacturing site’s 25-year history in contract manufacturing is a result of a solid cGMP compliance record, a quality-driven experienced staff and a customer-centric approach.

About MCP Pharmaceuticals, LLC

MCP Pharmaceuticals, headquartered in New Jersey, provides contract manufacturing of sterile products including biologics, small molecule, controlled substances, vaccines, ophthalmics, otics and antibiotics for large and small pharmaceutical and biotech organizations. MCP’s sterile manufacturing facility, located in Rochester Michigan sits on over 80 acres of land and includes a 171,000 sq. ft. production building and warehouse.

The production facility utilizes three high-speed filling lines, a clinical filling line and four lyophilizers. The site also includes separate facilities for chemistry, sterility testing, and analytical methods development. MCP has the capability to manufacture small-scale clinical through large-scale commercial products. MCP employs more than 370 staff in the USA in its manufacturing, product development, regulatory, sales and marketing and corporate areas. For more information, please visit jhppharma.com.

Additional Press Releases

04/17/13

MCP Pharmaceuticals To Produce Supplies of Biologic Drug Product For Late-Phase Clinical Trials

Webpage | PDF Format

12/31/12

MCP Pharmaceuticals Acquired By Warburg Pincus

Webpage | PDF Format

09/19/12

MCP Pharmaceuticals To Produce Lyophilized Biologic for International Late-Phase Clinical Trials

Webpage | PDF Format

06/07/12

MCP Pharmaceuticals Launches Generic Division